Comparer des méthodes
Examinez les méthodes sélectionnées côte à côte ; les lignes qui diffèrent sont mises en évidence.
| POEM (Patient-Oriented Eczema Measure)× | Skindex-29 (Instrument de Qualité de Vie pour les Maladies Cutanées)× | |
|---|---|---|
| Domaine | Dermatologie | Dermatologie |
| Famille | Process / pipeline | Process / pipeline |
| Année d'origine≠ | 2004 | 1997 |
| Auteur d'origine≠ | Charman CR, Venn AJ, Williams HC | Chren MM, Lasek RJ |
| Type | Self-report | Self-report |
| Source fondatrice≠ | Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519. DOI ↗ | Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. DOI ↗ |
| Alias≠ | POEM Score | Skindex, Skindex-QoL |
| Apparentées≠ | 2 | 1 |
| Résumé≠ | The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care. | Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes. |
| ScholarGateJeu de données ↗ |
|
|